Literature DB >> 15947112

Gonadotropins upregulate the epidermal growth factor receptor through activation of mitogen-activated protein kinases and phosphatidyl-inositol-3-kinase in human ovarian surface epithelial cells.

Jung-Hye Choi1, Kyung-Chul Choi, Nelly Auersperg, Peter C K Leung.   

Abstract

Gonadotropins, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) have been implicated as probable risk factors in epithelial ovarian carcinomas, most of which are derived from ovarian surface epithelium (OSE). Since epidermal growth factor (EGF) increases the growth of ovarian surface epithelial cells, we determined the effect of gonadotropins on the expression of epidermal growth factor receptor (EGFR). We investigated the basal levels of EGFR mRNA and protein, and the mechanisms involved in the regulation of EGFR at the transcriptional and translational levels by FSH and LH. The immortalized OSE cell lines (IOSE) derived from normal OSE cells by transfecting SV40 T-antigen (IOSE-80 and IOSE-80PC, a post-crisis line) and ovarian cancer cell lines were employed. A significantly lower level of EGFR was observed in both IOSE-80 and IOSE-80PC cells when compared with the ovarian cancer cell lines, OVCAR-3 and SKOV-3. Treatment of IOSE-80PC cells with FSH and LH (10(-7) and 10(-6) g/ml) resulted in a significant increase in EGFR mRNA at 24 h and EGFR protein at 48 h, whereas the treatment with gonadotropins for 24-48 h induced a mild increase in EGFR in OVCAR-3, but not in SKOV-3 cells. In addition, IOSE-80PC cells treated with gonadotropins and EGF (10 nM) exhibited an additive stimulation of mitogenesis. Further, FSH and LH significantly increased activities of various kinases at 5-10 min, and pre-treatments with LY294002 (an inhibitor of PI3K) or PD98059 (an inhibitor of ERK1/2) partially blocked the gonadotropin-induced up-regulation of EGFR in IOSE-80PC cells. We investigated whether the effect of gonadotropins on EGFR mRNA levels is induced by increased transcription and/or by altered mRNA stability. Treatment of IOSE-80PC cells with FSH (10(-7) and 10(-6) g/ml) significantly enhanced the activity of the EGFR promoter (120 and 140% increase, respectively) at 24 h, and treatment with LH (10(-7) g/ml) for 24 h induced an increase in the activity of EGFR promoter (30%) in these cells. On the other hand, LH resulted in a significant increase in EGFR mRNA stability in the decay curves. Taken together, these results suggest that the effect of gonadotropins on the expression of EGFR may affect cell growth via ERK-1/-2 and PI3K pathways in pre-neoplastic ovarian surface epithelial cells, and that FSH and LH increase EGFR mRNA by different mechanisms. The former increased EGFR gene transcription essentially, whereas the latter mainly enhanced EGFR mRNA stability.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15947112     DOI: 10.1677/erc.1.00896

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  21 in total

Review 1.  Possible role of Moringa oleifera Lam. root in epithelial ovarian cancer.

Authors:  Chinmoy K Bose
Journal:  MedGenMed       Date:  2007-02-06

2.  Luteinizing hormone inhibits cisplatin-induced apoptosis in human epithelial ovarian cancer cells.

Authors:  Lingfang Xia; Hao Wen; Xiaotian Han; Jia Tang; Yan Huang
Journal:  Oncol Lett       Date:  2016-01-18       Impact factor: 2.967

3.  BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.

Authors:  Britta Stordal; Kirsten Timms; Angela Farrelly; Danielle Gallagher; Steven Busschots; Mickaël Renaud; Julien Thery; Deborah Williams; Jennifer Potter; Thanh Tran; Greg Korpanty; Mattia Cremona; Mark Carey; Jie Li; Yang Li; Ozlem Aslan; John J O'Leary; Gordon B Mills; Bryan T Hennessy
Journal:  Mol Oncol       Date:  2013-01-31       Impact factor: 6.603

Review 4.  EGFR/HER-targeted therapeutics in ovarian cancer.

Authors:  Jason A Wilken; Tayf Badri; Sarah Cross; Rhoda Raji; Alessandro D Santin; Peter Schwartz; Adam J Branscum; Andre T Baron; Adam I Sakhitab; Nita J Maihle
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

5.  FSH stimulates ovarian cancer cell growth by action on growth factor variant receptor.

Authors:  Y Li; S Ganta; C Cheng; R Craig; R R Ganta; L C Freeman
Journal:  Mol Cell Endocrinol       Date:  2007-01-16       Impact factor: 4.102

6.  FSH enhances the proliferation of ovarian cancer cells by activating transient receptor potential channel C3.

Authors:  Xiang Tao; Naiqing Zhao; Hongyan Jin; Zhenbo Zhang; Yintao Liu; Jian Wu; Robert C Bast; Yinhua Yu; Youji Feng
Journal:  Endocr Relat Cancer       Date:  2013-05-30       Impact factor: 5.678

7.  Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.

Authors:  Yao-An Shen; Jiaxin Hong; Ryoichi Asaka; Shiho Asaka; Fang-Chi Hsu; Yohan Suryo Rahmanto; Jin-Gyoung Jung; Yu-Wei Chen; Ting-Tai Yen; Alicja Tomaszewski; Cissy Zhang; Nabeel Attarwala; Angelo M DeMarzo; Ben Davidson; Chi-Mu Chuang; Xi Chen; Stephanie Gaillard; Anne Le; Ie-Ming Shih; Tian-Li Wang
Journal:  Cancer Res       Date:  2020-08-28       Impact factor: 12.701

8.  Differential role of gonadotropin-releasing hormone on human ovarian epithelial cancer cell invasion.

Authors:  Chien-Lin Chen; Lydia W T Cheung; Man-Tat Lau; Jung-Hye Choi; Nelly Auersperg; Hsin-Shih Wang; Alice S T Wong; Peter C K Leung
Journal:  Endocrine       Date:  2007-06       Impact factor: 3.633

9.  Proliferation of the superficial epithelium of ovaries in senile female rats following oral administration of conjugated equine estrogens.

Authors:  Sergio Eduardo Perniconi; Manuel de Jesus Simões; Ricardo Dos Santos Simões; Mauro Abi Haidar; Edmund C Baracat; Jose Maria Soares
Journal:  Clinics (Sao Paulo)       Date:  2008-06       Impact factor: 2.365

10.  Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.

Authors:  Doris R Siwak; Mark Carey; Bryan T Hennessy; Catherine T Nguyen; Mollianne J McGahren Murray; Laura Nolden; Gordon B Mills
Journal:  J Oncol       Date:  2009-11-19       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.